Drug interactions and the evolution of antibiotic resistance
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Large-scale, systems biology approaches now allow us to systematically map synergistic and antagonistic interactions between drugs. Consequently, drug antagonism is emerging as a powerful tool to study biological function and relatedness between cellular components as well as to uncover mechanisms of drug action. Furthermore, theoretical models and new experiments suggest that antagonistic interactions between antibiotics can counteract the evolution of drug resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the interactions can be highly dosedependent”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antibiotics in Laboratory Medicine.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-4-653_4 · Cited by 2,779
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Systematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
Global Mapping of the Yeast Genetic Interaction Network
Tong, A. H. Y., Lesage, G., Bader, G. D., Ding, H., Xu, H., Xin, X., Young, J., Berriz, G. F., Brost, R. L., Chang, M., et al. (2004) · Science · doi:10.1126/science.1091317 · Cited by 2,095
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Schuldiner, M., Collins, S. R., Thompson, N. J., Denic, V., Bhamidipati, A., Punna, T., Ihmels, J., Andrews, B., Boone, C., Greenblatt, J. F., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.031 · Cited by 870
Collins, S. R., Miller, K. M., Maas, N. L., Roguev, A., Fillingham, J., Chu, C. S., Schuldiner, M., Gebbia, M., Recht, J., Shales, M., et al. (2007) · Nature · doi:10.1038/nature05649 · Cited by 869
Modular epistasis in yeast metabolism
Segrè, D., DeLuna, A., Church, G. M., & Kishony, R. (2005) · Nature Genetics · doi:10.1038/ng1489 · Cited by 575
Self-citationEpistasis and the Evolutionary Process
Hurst, L. D. (2000) · Heredity · doi:10.1046/j.1365-2540.2000.0846b.x · Cited by 563
A DNA Integrity Network in the Yeast Saccharomyces cerevisiae
Pan, X., Ye, P., Yuan, D. S., Wang, X., Bader, J. S., & Boeke, J. D. (2006) · Cell · doi:10.1016/j.cell.2005.12.036 · Cited by 537 · cited 1×
“Systematic screens for synergy between double gene knockouts have been successfully used to understand biological systems in bacteria and yeas”
Cited by
Origins and evolution of antibiotic resistance
Davies, J., & Davies, D. (2010) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00016-10 · Cited by 5,784
“Is it possible that older and/or unused (or even discarded) antibiotics might be rehabilitated for “last-resort” use in rational combinations to overcome multidrug-resistant bacterial infections, as some studies have suggested (152)? Many strategies for avoiding, inhibiting, or bypassing resistance mechanisms in patho…”
BackgroundHow antibiotics kill bacteria: from targets to networks
Kohanski, M. A., Dwyer, D. J., & Collins, J. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2333 · Cited by 2,258
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace
Chinemerem Nwobodo, D., Ugwu, M. C., Oliseloke Anie, C., Al‐Ouqaili, M. T. S., Chinedu Ikem, J., Victor Chigozie, U., & Saki, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24655 · Cited by 985
Evolutionary paths to antibiotic resistance under dynamically sustained drug selection
Toprak, E., Veres, A., Michel, J.-B., Chait, R., Hartl, D. L., & Kishony, R. (2012) · Nature Genetics · doi:10.1038/ng.1034 · Cited by 764
Self-citationAntibiotics produced by Streptomyces
de Lima Procópio, R. E., da Silva, I. R., Martins, M. K., de Azevedo, J. L., & de Araújo, J. M. (2012) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2012.08.014 · Cited by 735
Phenotypic Landscape of a Bacterial Cell
Nichols, R. J., Sen, S., Choo, Y. J., Beltrao, P., Zietek, M., Chaba, R., Lee, S., Kazmierczak, K. M., Lee, K. J., Wong, A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.052 · Cited by 713
Multidrug evolutionary strategies to reverse antibiotic resistance
Baym, M., Stone, L. K., & Kishony, R. (2016) · Science · doi:10.1126/science.aad3292 · Cited by 710
Self-citationZitnik, M., Nguyen, F., Wang, B., Leskovec, J., Goldenberg, A., & Hoffman, M. M. (2019) · Information Fusion · doi:10.1016/j.inffus.2018.09.012 · Cited by 675
“It is often defined through the concepts of synergy and antagonism [251].”
BackgroundPredicting drug response and synergy using a deep learning model of human cancer cells
Kuenzi, B. M., Park, J., Fong, S. H., Sanchez, K. S., Lee, J., Kreisberg, J. F., Ma, J., & Ideker, T. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.09.014 · Cited by 544
“The parallel pathway inhibition theory of drug synergy (Yeh et al., 2009) holds that two drugs will be synergistic if they inhibit separate pathways that regulate a common essential function (Figure 5A).”
BackgroundProbiotics, prebiotics, and postbiotics in health and disease
Ji, J., Jin, W., Liu, S., Jiao, Z., & Li, X. (2023) · MedComm · doi:10.1002/mco2.420 · Cited by 384
“73 Nonadherence to prescribed treatment regimens due to complexity, forgetfulness, or concerns about side effects can also reduce medicine effectiveness and cause complications.”
BackgroundThe rapid spread of carbapenem-resistant Enterobacteriaceae
Potter, R. F., D’Souza, A. W., & Dantas, G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.09.002 · Cited by 403
Gao, G., Lange, D., Hilpert, K., Kindrachuk, J., Zou, Y., Cheng, J. T. J., Kazemzadeh-Narbat, M., Yu, K., Wang, R., Straus, S. K., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.02.013 · Cited by 388
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367
Therapeutic strategies to combat antibiotic resistance
Brooks, B. D., & Brooks, A. E. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.027 · Cited by 367
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“As with any complex system, the interactions can be highly dosedependent (Hegreness et al. 2008; Kohanski et al. 2010; Yeh et al. 2009).”
BackgroundSpecies-specific activity of antibacterial drug combinations
Brochado, A. R., Telzerow, A., Bobonis, J., Banzhaf, M., Mateus, A., Selkrig, J., Huth, E., Bassler, S., Zamarreño Beas, J., Zietek, M., et al. (2018) · Nature · doi:10.1038/s41586-018-0278-9 · Cited by 357
Systematic exploration of synergistic drug pairs
Cokol, M., Chua, H. N., Tasan, M., Mutlu, B., Weinstein, Z. B., Suzuki, Y., Nergiz, M. E., Costanzo, M., Baryshnikova, A., Giaever, G., et al. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.71 · Cited by 315
“One model for drug synergy is the parallel pathway inhibition model, which suggests that two drugs will be synergistic if they inhibit two proteins on parallel pathways essential for an observed phenotype (Yeh et al, 2009).”
Antagonism between Bacteriostatic and Bactericidal Antibiotics Is Prevalent
Ocampo, P. S., Lázár, V., Papp, B., Arnoldini, M., Abel zur Wiesch, P., Busa-Fekete, R., Fekete, G., Pál, C., Ackermann, M., & Bonhoeffer, S. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02463-14 · Cited by 284
Inhibition of Retrograde Transport Protects Mice from Lethal Ricin Challenge
Stechmann, B., Bai, S.-K., Gobbo, E., Lopez, R., Merer, G., Pinchard, S., Panigai, L., Tenza, D., Raposo, G., Beaumelle, B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.01.043 · Cited by 290
“Such protection of one drug (our small molecule inhibitors) against the action of another (ricin or SLTs) falls under the general phenomena of suppressive drug interactions (Fraser, 1872; Yeh et al., 2009).”
Understanding, predicting and manipulating the genotypic evolution of antibiotic resistance
Palmer, A. C., & Kishony, R. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3351 · Cited by 285
Self-citationOz, T., Guvenek, A., Yildiz, S., Karaboga, E., Tamer, Y. T., Mumcuyan, N., Ozan, V. B., Senturk, G. H., Cokol, M., Yeh, P., et al. (2014) · Molecular Biology and Evolution · doi:10.1093/molbev/msu191 · Cited by 275
“Several systematic studies have been conducted to characterize interactions between drug pairs and biological mechanisms behind drug–drug interactions (Yeh et al. 2006, 2009; Bollenbach et al. 2009; Cokol et al. 2011).”
BackgroundSelf-citationZharkova, M. S., Orlov, D. S., Golubeva, O. Y., Chakchir, O. B., Eliseev, I. E., Grinchuk, T. M., & Shamova, O. V. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00128 · Cited by 272
“They applies to the cases when the ways in which interacting compounds perform their individual action converge at some specific site; for example, if two drugs are inhibiting alternative pathways producing the same essential metabolite (Jia et al., 2009; Yeh et al., 2009), or if they share the same target, but bind n…”
BackgroundCombined Use of Biocontrol Agents to Manage Plant Diseases in Theory and Practice
Xu, X.-M., Jeffries, P., Pautasso, M., & Jeger, M. J. (2011) · Phytopathology® · doi:10.1094/phyto-08-10-0216 · Cited by 266
Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance
Kim, S., Lieberman, T. D., & Kishony, R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409800111 · Cited by 264
“Other factors might also affect the efficacy of such treatments, including competition (clonal interference) among resistant mutants, lasting nongenetic effects of drugs on bacterial physiology (43), effects of drugs on rate of mutations (44), and synergy and antagonism between the drugs (17).”
BackgroundSelf-citationAntimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution
Bollenbach, T. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.05.008 · Cited by 261
Combination therapies for combating antimicrobial resistance
Fischbach, M. A. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.08.003 · Cited by 259
Evolution of acquired resistance to anti-cancer therapy
Foo, J., & Michor, F. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.02.025 · Cited by 254
“Recent studies have shown that drug antagonism between antibiotics may slow the evolution of bacterial resistance (Yeh et al., 2009).”
BackgroundMacLean, R. C., Hall, A. R., Perron, G. G., & Buckling, A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2778 · Cited by 247
“For example, recent experimental work has shown physiological interactions between antibiotics can affect the rate of evolution of multidrug resistanc”
BackgroundRapid screening of antibiotic toxicity in an automated microdroplet system
Churski, K., Kaminski, T. S., Jakiela, S., Kamysz, W., Baranska-Rybak, W., Weibel, D. B., & Garstecki, P. (2012) · Lab on a Chip · doi:10.1039/c2lc21284f · Cited by 228
Combination Effects of Antimicrobial Peptides
Yu, G., Baeder, D. Y., Regoes, R. R., & Rolff, J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02434-15 · Cited by 220
“Synergism, albeit not within a pharmacodynamics framework, has been reported for 2-way combinations of antibiotics (8, 42), AMPs (16, 17, 24), antimicrobial peptoids (43), antibiotics and AMPs (44, 45), and AMPs and antimicrobial peptoids (43).”
Backgroundde Visser, J. A. G. M., Cooper, T. F., & Elena, S. F. (2011) · Proceedings of the Royal Society B: Biological Sciences · doi:10.1098/rspb.2011.1537 · Cited by 214
Pena-Miller, R., Laehnemann, D., Jansen, G., Fuentes-Hernandez, A., Rosenstiel, P., Schulenburg, H., & Beardmore, R. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001540 · Cited by 209
“To make our discussion more precise we say that a pair of bacteriostatic antibiotics of equal efficacy is synergistic if a 50-50 weighted combination of both drugs inhibits growth more than the two single-drug treatments when measured over one day of bacterial growth [8,14–16].”
BackgroundBifunctional antimicrobial conjugates and hybrid antimicrobials
Klahn, P., & Brönstrup, M. (2017) · Natural Product Reports · doi:10.1039/c7np00006e · Cited by 181
Munck, C., Gumpert, H. K., Wallin, A. I. N., Wang, H. H., & Sommer, M. O. A. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009940 · Cited by 178
Compensation of Fitness Costs and Reversibility of Antibiotic Resistance Mutations
Schulz zur Wiesch, P., Engelstädter, J., & Bonhoeffer, S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01460-09 · Cited by 169
Scandorieiro, S., de Camargo, L. C., Lancheros, C. A. C., Yamada-Ogatta, S. F., Nakamura, C. V., de Oliveira, A. G., Andrade, C. G. T. J., Duran, N., Nakazato, G., & Kobayashi, R. K. T. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00760 · Cited by 161
Torres-Barceló, C., Arias-Sánchez, F. I., Vasse, M., Ramsayer, J., Kaltz, O., & Hochberg, M. E. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106628 · Cited by 166
“Despite their potential, combined antimicrobial therapies are subject to the evolution of resistance due to convergent mechanisms of resistance if they target similar pathways, and the specific combination will determine the speed of resistance evolution [11].”
BackgroundInfluentialA systems analysis of mutational effects in HIV-1 protease and reverse transcriptase
Hinkley, T., Martins, J., Chappey, C., Haddad, M., Stawiski, E., Whitcomb, J. M., Petropoulos, C. J., & Bonhoeffer, S. (2011) · Nature Genetics · doi:10.1038/ng.795 · Cited by 165
Optimal Drug Synergy in Antimicrobial Treatments
Torella, J. P., Chait, R., & Kishony, R. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000796 · Cited by 162
“We assume that single-drug resistant mutants are affected by only one of the drugs, which is reasonable in the case of resistance mechanisms that decrease the intracellular concentration of antibiotic, such as efflux pump expression or enzymatic degradation [11,13,30].”
BackgroundSelf-citationPrediction of multidimensional drug dose responses based on measurements of drug pairs
Zimmer, A., Katzir, I., Dekel, E., Mayo, A. E., & Alon, U. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606301113 · Cited by 152
“The model is even capable of capturing hyperantagonism (47), where the pair has a lower effect than either of the two single drugs [such as the pair trimethoprim−lincomycin (Fig.”
BackgroundA Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering
To, T., Cuadros, A. M., Shah, H., Hung, W. H. W., Yang, L., Kim, S. H., Rubin, D. H. F., Boe, R. H., Rath, S. P., Eaton, J. K., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.032 · Cited by 147
“We note that this type of intra-system suppression has previously been described in the context of antibiotic actions (Bollenbach et al., 2009; Yeh et al., 2009), but to our knowledge, it has never before been reported in a mammalian system, and certainly not described in the context of mitochondrial physiology.”
BackgroundSynergistic and Antagonistic Drug Combinations Depend on Network Topology
Yin, N., Ma, W., Pei, J., Ouyang, Q., Tang, C., & Lai, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093960 · Cited by 139
“[4,20] categorized drug antagonism into two categories: antagonistic buffering and antagonistic suppression.”
BackgroundPalmer, A. C., Chidley, C., & Sorger, P. K. (2019) · eLife · doi:10.7554/elife.50036 · Cited by 133
“The significance of antagonism among some drug pairs is not clear but studies of antibiotics have shown that antagonistic drug interactions can suppress the emergence of drug-resistant mutants (Chait et al., 2007; Michel et al., 2008; Yeh et al., 2009).”
BackgroundSynergy of Silver Nanoparticles and Aztreonam against Pseudomonas aeruginosa PAO1 Biofilms
Habash, M. B., Park, A. J., Vis, E. C., Harris, R. J., & Khursigara, C. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03170-14 · Cited by 134
Dual-acting hybrid antibiotics: a promising strategy to combat bacterial resistance
Pokrovskaya, V., & Baasov, T. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.508069 · Cited by 147
“Although the strategy of hybrid antibiotics development is principally based on the “multivalent therapy” approach [23,72], a strategy with a hypothesized advantage in slowing down the emergence of spontaneous target-related resistance development relative to “monovalent therapy”, the reality is that this issue in the…”
InfluentialDhama, K., Tiwari, R., Chakrabort, S., Saminathan, M., Kumar, A., Karthik, K., Wani, M. Y., AMARPAL, A., Singh, S. V., & Rahal, A. (2013) · International Journal of Pharmacology · doi:10.3923/ijp.2014.1.43 · Cited by 169
Mapping the Environmental Fitness Landscape of a Synthetic Gene Circuit
Nevozhay, D., Adams, R., Itallie, E. S. V., Bennett, M. R., & Balázsi, G. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002480 · Cited by 134
“To predict cell population fitness in various combinations of the inducer and the antibiotic, we assumed that the joint effects of these molecules followed Bliss independence [59].”
BackgroundPhysicochemical Features and Peculiarities of Interaction of AMP with the Membrane
Pirtskhalava, M., Vishnepolsky, B., Grigolava, M., & Managadze, G. (2021) · Pharmaceuticals · doi:10.3390/ph14050471 · Cited by 121
“Recent studies report that success depends on the results of the combination, which can be synergistic or antagonistic [153,154].”
BackgroundAntibiotic combinations reduce Staphylococcus aureus clearance
Lázár, V., Snitser, O., Barkan, D., & Kishony, R. (2022) · Nature · doi:10.1038/s41586-022-05260-5 · Cited by 129
Self-citationRaymond, B. (2019) · Evolutionary Applications · doi:10.1111/eva.12808 · Cited by 126
de Evgrafov, M. C. R., Gumpert, H., Munck, C., Thomsen, T. T., & Sommer, M. O. A. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msv006 · Cited by 121
Epistasis and the Evolution of Antimicrobial Resistance
Wong, A. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00246 · Cited by 125
“of multi-drug therapy should be to slow or prevent the evolution of resistance (Chait et al., 2007; Yeh et al., 2009; Imamovic and Sommer, 2013; Palmer and Kishony, 2013; Bollenbach, 2015; Baym et al., 2016), rather than to clear infections quickly.”
BackgroundPostek, W., & Garstecki, P. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00729 · Cited by 117
The Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 109
“Indeed, while pathogens are able to rapidly acquire resistance to single target agents through mutations in the target protein, it is much more difficult to acquire resistance to multiple target agents, since a mutation in one of the essential target proteins would not confer any selective advantage over the wildtype…”
BackgroundFarha, M. A., Czarny, T. L., Myers, C. L., Worrall, L. J., French, S., Conrady, D. G., Wang, Y., Oldfield, E., Strynadka, N. C. J., & Brown, E. D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511751112 · Cited by 104
“Like synergism, antagonism typically has a genetic basis that reflects relationships between cellular targets and mechanisms of drug action (7).”
BackgroundA Computational Approach for Identifying Synergistic Drug Combinations
Gayvert, K. M., Aly, O., Platt, J., Bosenberg, M. W., Stern, D. F., & Elemento, O. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005308 · Cited by 97
The inoculum effect and band‐pass bacterial response to periodic antibiotic treatment
Tan, C., Smith, R. P., Srimani, J. K., Riccione, K. A., Prasada, S., Kuehn, M. J., & You, L. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.49 · Cited by 113
“In addition to developing new antibiotics, there is a critical need to design better treatment protocols by using existing antibiotics (Levy and Marshall, 2004; Yeh et al, 2009).”
Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms
Zhang, Q., & Buckling, A. (2012) · Evolutionary Applications · doi:10.1111/j.1752-4571.2011.00236.x · Cited by 104
“Simultaneous use of phages and antibiotics may help to minimize the chance of resistance evolution for the same reasons as treatment with multiple antibiotics (Bonhoeffer et al. 1997; Lipsitch and Levin 1997; Chow and Yu 1999; Yeh et al. 2009; zur Wiesch et al. 2011).”
BackgroundMaifiah, M. H. M., Creek, D. J., Nation, R. L., Forrest, A., Tsuji, B. T., Velkov, T., & Li, J. (2017) · Scientific Reports · doi:10.1038/srep45527 · Cited by 103
“These modifications significantly reduce the negative charge on the bacterial outer membrane, thus diminishing the binding of polymyxins 10 .”
BackgroundGenetic and Genomic Architecture of the Evolution of Resistance to Antifungal Drug Combinations
Hill, J. A., Ammar, R., Torti, D., Nislow, C., & Cowen, L. E. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003390 · Cited by 93
“Drug interactions have tremendous potential to influence the evolution of drug resistance [84].”
BackgroundSuppressive drug combinations and their potential to combat antibiotic resistance
Singh, N. P., & Yeh, P. J. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2017.102 · Cited by 107
Self-citationZhang, X., Lin, B., Li, X., Wang, X., Huang, K., & Chen, Z. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2021.132728 · Cited by 105
Guimerà, R., & Sales‐Pardo, M. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003374 · Cited by 101
“Antagonistic interactions can be used to study the mechanisms of action of drugs [4], and even suppressing interactions between drugs, in which one drug inhibits the action of the other, have been found to be potentially very relevant in the fight against antibiotic-resistant pathogens [5].”
BackgroundASDCD: Antifungal Synergistic Drug Combination Database
Chen, X., Ren, B., Chen, M., Liu, M.-X., Ren, W., Wang, Q.-X., Zhang, L.-X., & Yan, G.-Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086499 · Cited by 84
“Several models are helpful in understanding synergistic effect: 1) the physical interaction model suggests that two drugs with physical interactions tend to be a more potential synergistic combination [13];2) the same target model involves two synergistic drugs that tend to target different sites of the same protein […”
BackgroundMiller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004014 · Cited by 86
“Second, in agreement with the parallel pathway hypothesis model for drug synergy (17, 21, 22), the most Miller et al.”
The future of antibiotics begins with discovering new combinations
Zhu, M., Tse, M. W., Weller, J., Chen, J., & Blainey, P. C. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14649 · Cited by 99
Collateral sensitivity constrains resistance evolution of the CTX-M-15 β-lactamase
Rosenkilde, C. E. H., Munck, C., Porse, A., Linkevičius, M., Andersson, D. I., & Sommer, M. O. A. (2019) · Nature Communications · doi:10.1038/s41467-019-08529-y · Cited by 86
HSP90 as a platform for the assembly of more effective cancer chemotherapy
Whitesell, L. J., & Lin, N. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.12.006 · Cited by 95
Evolutionary stability of antibiotic protection in a defensive symbiosis
Engl, T., Kroiß, J., Kai, M., Nechitaylo, T. Y., Svatoš, A., & Kaltenpoth, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1719797115 · Cited by 89
“First, if at least two compounds act antagonistically, a microorganism that evolves resistance to only one of the compounds experiences a higher effective inhibition by the remaining compound and thus, has a decreased fitness compared with nonresistant cells (78, 79).”
BackgroundSpagnolo, F., Trujillo, M., & Dennehy, J. J. (2021) · mBio · doi:10.1128/mbio.01966-21 · Cited by 111
“Further, multimember community action is implicated as combinations of antibiotic-classes present can enhance or antagonize the effects of an antibiotic overall (52), leading to additional community-level filtering capacity.”
BackgroundMelioidosis: Clinical impact and public health threat in the tropics
Samy, R. P., Stiles, B. G., Sethi, G., & Lim, L. H. K. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004738 · Cited by 90
RetractedBeyond killing: Can we find new ways to manage infection?
Vale, P. F., McNally, L., Doeschl‐Wilson, A., King, K. C., Popat, R., Domingo-Sananes, M. R., Allen, J. E., Soares, M. P., & Kümmerli, R. (2016) · Evolution Medicine and Public Health · doi:10.1093/emph/eow012 · Cited by 85
“However, the evolution of drug resistance appears to be inevitable (despite some interesting exceptions such as the continued susceptibility of Treponema pallidum [5] and Streptococcus pyogenes [6] to penicillin), meaning that novel antimicrobial drugs will only offer at best a temporary solution [7, 8].”
BackgroundMerker, M., Tüeffers, L., Vallier, M., Groth, E. E., Sonnenkalb, L., Unterweger, D., Baines, J. F., Niemann, S., & Schulenburg, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01938 · Cited by 88
Morales‐Durán, N., León‐Buitimea, A., & Morones‐Ramírez, J. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27984 · Cited by 91
“…combination therapies, the interactions between antibiotics play an essential role in treating resistant antibiotics since they can present synergistic, additive, or antagonistic effects that, when determined, can propose treatment strategies that use a combination of more effective drugs [99,100].”
BackgroundPerelshtein, I., Applerot, G., Perkas, N., Grinblat, J., Hulla, E., Wehrschuetz-Sigl, E., Hasmann, A., Guebitz, G. M., & Gedanken, A. (2010) · ACS Applied Materials & Interfaces · doi:10.1021/am100291w · Cited by 77
Using Combination Therapy to Thwart Drug Resistance
Hill, J. A., & Cowen, L. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.68 · Cited by 75
Xia, J., Xin, L., Li, J., Tian, L., Wu, K.-X., Zhang, S., Yan, W., Li, H., Zhao, Q., & Liang, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02135 · Cited by 73
Saputra, E. C., Huang, L., Chen, Y., & Tucker‐Kellogg, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1201 · Cited by 82
“In the fi eld of infectious diseases, work by Kishony and colleagues (18 – 21) discovered that antagonistic antibiotic combinations could delay the development of bacterial resistance.”
Isolated cell behavior drives the evolution of antibiotic resistance
Artemova, T., Gerardin, Y., Dudley, C., Vega, N. M., & Gore, J. (2015) · Molecular Systems Biology · doi:10.15252/msb.20145888 · Cited by 79
Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment
Gomez, J. E., Kaufmann-Malaga, B., Wivagg, C. N., Kim, P. B., Silvis, M. R., Renedo, N., Ioerger, T. R., Ahmad, R., Livny, J., Fishbein, S. R. S., et al. (2017) · eLife · doi:10.7554/elife.20420 · Cited by 79
“We performed 2D checkerboard experiments (Figure 3C), diluting a protein synthesis inhibitor horizontally and a test antibiotic (CIP or INH) vertically across 384-well plates, with the pattern of outgrowth indicating how the two antibiotics interact (DePristo et al., 2007; Yeh et al., 2009).”
MethodPrediction of ultra-high-order antibiotic combinations based on pairwise interactions
Katzir, I., Cokol, M., Aldridge, B. B., & Alon, U. S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006774 · Cited by 77
Survival of Bactericidal Antibiotic Treatment by a Persister Subpopulation of Listeria monocytogenes
Knudsen, G. M., Ng, Y., & Gram, L. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.02184-13 · Cited by 80
“This so-called Eagle effect (44) was first described over 60 years ago; however, the mechanism is still not fully understood (43).”
BackgroundChakrabarti, S., & Michor, F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2871 · Cited by 72
“3A and B are well known signatures of additivity and synergy, respectively, within the framework of the Loewe model (40, 41).”
InfluentialCatteau, L., Li, Z., Bambeke, F. V., & Quetin‐Leclercq, J. (2018) · Phytochemistry Reviews · doi:10.1007/s11101-018-9564-2 · Cited by 79
Additivity of inhibitory effects in multidrug combinations
Russ, D., & Kishony, R. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0252-1 · Cited by 71
Self-citationBacteria responsive antibacterial surfaces for indwelling device infections
Traba, C., & Liang, J. F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.025 · Cited by 68
“However, some unsolved problems are associated with current antibiotic impregnations: 1) since antibiotics for resistant bacteria such as MRSA are very limited at the present time [11, 12], antibiotic impregnations do not work in resistant mutant involved infections; 2) antibiotic impregnations usually have narrowed a…”
BackgroundRukhlenko, O. S., Khorsand, F., Krstić, A., Rožanc, J., Alexopoulos, L. G., Rauch, N., Erickson, K. E., Hlavacek, W. S., Posner, R. G., Gómez‐Coca, S., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.002 · Cited by 72
“Loewe isoboles are straight lines for non-interacting drugs: Drug interactions are commonly described in terms of the Bliss independence or the Loewe additivity, synergy and antagonism (Yeh et al., 2009).”
BackgroundPredictive model identifies key network regulators of cardiomyocyte mechano-signaling
Tan, P. M., Buchholz, K. S., Omens, J. H., McCulloch, A. D., & Saucerman, J. J. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005854 · Cited by 66
Zhang, S., Wang, J., & Ahn, J. (2023) · Antibiotics · doi:10.3390/antibiotics12091417 · Cited by 75
“Nevertheless, mixed antibiotics may exhibit complicated interactions between antibiotics and unmatched pharmacokinetics, ultimately making it difficult to predict synergistic antimicrobial effects [14].”
BackgroundUsing adjuvants and environmental factors to modulate the activity of antimicrobial peptides
Walkenhorst, W. F. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2015.12.034 · Cited by 69
Mechanisms and therapeutic potential of collateral sensitivity to antibiotics
Roemhild, R., & Andersson, D. I. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009172 · Cited by 71
“Antibiotic synergy refers to the nonlinear increase of inhibition when antibiotics are applied in mixture [6], and negative hysteresis refers to a transient increase of antibiotic efficacy to 1 drug after a short preceding exposure to another drug [7].”
BackgroundComprehensive review on mechanism of action, resistance and evolution of antimycobacterial drugs
Chauhan, A., Kumar, M., Kumar, A., & Kanchan, K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119301 · Cited by 71
Wambaugh, M. A., Shakya, V. P. S., Lewis, A. J., Mulvey, M. A., & Brown, J. C. S. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2001644 · Cited by 63
The risk of low concentrations of antibiotics in agriculture for resistance in human health care
ter Kuile, B. H., Kraupner, N., & Brul, S. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw210 · Cited by 83
“Lately, epistatic interactions between various drugs have been investigated regarding their potential to enhance or decrease the development of antibiotic resistance (Yeh et al. 2009).”
Mechanisms of drug interactions between translation-inhibiting antibiotics
Kavčič, B., Tkačik, G., & Bollenbach, T. (2020) · Nature Communications · doi:10.1038/s41467-020-17734-z · Cited by 65
The microbial network property as a bio-indicator of antibiotic transmission in the environment
Gao, Q., Gao, S.-H., Bates, C. T., Zeng, Y., Lei, J., Su, H., Dong, Q., Qin, Z., Zhao, J., Zhang, Q., et al. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.143712 · Cited by 73
Comparing Selection on S. aureus between Antimicrobial Peptides and Common Antibiotics
Dobson, A. J., Purves, J., Kamysz, W., & Rolff, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076521 · Cited by 61
“However we speculate that this is likely to be a general phenomenon, which is dependent on the nature of the functional interaction between the compounds, similar to effects of combinatorial administration on evolution of antibiotic resistance [26,27,28].”
BackgroundBrochado, A. R., & Typas, A. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.01.008 · Cited by 64
Shang, R., Pu, X., Xu, X., Xin, Z., Zhang, C., Guo, W., Liu, Y., & Liang, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500374c · Cited by 61
Metadata
- Authors
- Yeh, P. J., Hegreness, M. J., Aiden, A. P., & Kishony, R.
- Affiliations
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Kishony, Roy
- Venue
- Nature Reviews Microbiology
- Published
- 2009-06
- Volume
- 7
- Issue
- 6
- Pages
- 460-466
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- PMC
- PMC2855488
- OpenAlex
- W2115076532
- Cited by
- 350
- References
- 68
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 23 · 2023: 29 · 2022: 22 · 2021: 27 · 2020: 14 · 2019: 23 · 2018: 22 · 2017: 29 · 2016: 23 · 2015: 16 · 2014: 31 · 2013: 20 · 2012: 13
- FWCI
- 0.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Science Foundation
- National Institutes of Health
- National Defense Science and Engineering Graduate
- National Institute of General Medical Sciences (R01GM081617)
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- drug interactions, antibiotic resistance, drug antagonism, drug synergy, systems biology, mechanisms of drug action, resistance evolution
- MeSH terms
- Drug Antagonism, Drug Interactions, Drug Resistance, Microbial, Drug Synergism, Models, Theoretical, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.